Matinas BioPharma ( (MTNB) ) has released a notification of late filing.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Matinas Biopharma Holdings, Inc. has announced a delay in filing its Form 10-K (Yearly Report) for the financial period ending December 31, 2024. The company cites the need for additional time to complete the review of its financial statements as the primary reason for the delay, which could not be avoided without unreasonable effort or expense. Matinas Biopharma plans to file the report within the 15-day extension period allowed under Rule 12b-25. The company does not anticipate any significant changes in financial results from the previous fiscal year. Matinas Biopharma is committed to maintaining compliance and has authorized this notification with the signature of Keith A. Kucinski, Chief Financial Officer.
More about Matinas BioPharma
YTD Price Performance: -8.16%
Average Trading Volume: 456,317
Technical Sentiment Signal: Strong Buy
Current Market Cap: $2.75M
See more insights into MTNB stock on TipRanks’ Stock Analysis page.